Strand Life Sciences Pvt. Ltd

Strand Life Sciences Pvt. Ltd is a biotechnology firm specializing in genomic solutions and bioinformatics services, focusing on clinical applications such as next-generation sequencing and biomarker discovery. Founded in 2000 in Bangalore, India, Strand Life Sciences Pvt. Ltd focuses on genomic and bioinformatics services for clinical applications.

The company has undergone strategic pivots, enhancing its technology stack, particularly in next-generation sequencing. Ramesh Hariharan and Vijay Chandru are the founders of the company. As of September 2020, the company was acquired by Oncquest Laboratories Ltd, with the financial details not disclosed. The company has raised a total of INR 836.

00 mn, with the latest funding round led by Quadria Capital Investment Management and involving investors HealthQuad and IMC Investments. Strand Life Sciences specializes in a comprehensive range of genomic solutions and bioinformatics services tailored for clinical applications. Their offerings include an automated reporting platform for somatic and germline next-generation sequencing tests, data generation and curation services focusing on single-cell and spatial transcriptomics, and software development for complex omics data analysis. Their clientele includes academic institutions and pharmaceutical companies across North America and Europe, addressing challenges in precision medicine.

In the most recent fiscal year 2023, Strand Life Sciences reported a revenue amounting to INR 10,025,470. 40 and an EBITDA of INR 964,021. 10. The company operates primarily on a B2B model, generating revenue through contracts and partnerships, particularly in the pharmaceutical and biotechnology sectors, offering subscription-based access to their platforms and analytical tools.

Strand Life Sciences plans to innovate and expand its product offerings, focusing on new genomic tools and enhancing their bioinformatics services. They are targeting expansion into additional markets in North America and Europe by 2025, utilizing the funds raised in their recent financing round to support these initiatives. The company aims to leverage its recent acquisition by Oncquest Laboratories Ltd to broaden its outreach and capabilities in precision medicine.